Hexagon Purus ASA's second quarter results 2025 will be released on 17 July 2025, 07:00 CET. Morten Holum (CEO) and Salman Alam (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live via https://hexagonpurus.vivida.live. The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com. For more information: Mathias Meidell, IR Director, Hexagon Purus ASATelephone: +47 909 82 242 | mathias.meidell ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Apple Inc. (NASDAQ: AAPL) and certain of the Company's senior executives for potential violations of the federal securities laws. Why was Apple Sued for Securities Fraud? Apple is a multinational technology company that engages primarily in the businesses of smart-devices and artificial intelligence ("AI"). Apple's software includes a digital personal assistant c ...

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research ...

SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC Disease Progression TEL AVIV, Israel and GLASGOW, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology c ...

99.1 Presentation slides dated May 20, 2024 6 7 9 8 10 11 12 13 16 14 15 17 ...

The Semler Vision: Medical and Monetary Freedom Empowering Early Detection. Backed by Bitcoin. June 3, 2025 Semler Scientific® Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the us of forward-looking terminology, including the terms" believe, ""expect," "plon," "intend," "may, "could," "intend," "may, "could," "might,"" will," "should," or, in each ca their neqqtiv ...

Shares in data center company and real estate investment trust (REIT) Equinix (EQIX -7.92%) were lower by nearly 10% by noon ET today. The decline comes after a slew of Wall Street analysts downgraded the stock the day after its analyst day presentation.Here's what the investment community is worried about.Analyst downgradesIn truth, the decline is probably a combination of lofty expectations going into the analyst day presentation (not least because data centers and artificial intelligence, or AI, are the ...

LONDON, June 26, 2025 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a virtual presentation to discuss the Company’s unaudited results for the second quarter and first half of 2025 on Thursday, July 3, 2025 at 15:00 CEST (09:00 EDT, 14:00 BST). The virtual presentation will be hosted by: - Mr. Udo Lange - Chief Executive Officer, Stolt-Nielsen Limited - Mr. Jens F. Grüner-Hegge - Chief Financial Officer, Stolt-Nielsen Limited- Mr. Alex Ng - Vice President Strategy & Business Development, Stolt-Nielsen L ...

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile Full study data from both cohorts expected later this year BARCELONA, Spain, June 26, 2025 (GLOBE NEWSWIRE) -- The Australasian Gastro-In ...

JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) ...